GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (LTS:0RBP) » Definitions » EBITDA Margin %

Kiadis Pharma NV (LTS:0RBP) EBITDA Margin % : -348.85% (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kiadis Pharma NV's EBITDA for the six months ended in Dec. 2020 was €-61.05 Mil. Kiadis Pharma NV's Revenue for the six months ended in Dec. 2020 was €17.50 Mil. Therefore, Kiadis Pharma NV's EBITDA margin for the quarter that ended in Dec. 2020 was -348.85%.


Kiadis Pharma NV EBITDA Margin % Historical Data

The historical data trend for Kiadis Pharma NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV EBITDA Margin % Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -442.85

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -348.85

Competitive Comparison of Kiadis Pharma NV's EBITDA Margin %

For the Biotechnology subindustry, Kiadis Pharma NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's EBITDA Margin % falls into.



Kiadis Pharma NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kiadis Pharma NV's EBITDA Margin % for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2020 )/Revenue (A: Dec. 2020 )
=-77.499/17.5
=-442.85 %

Kiadis Pharma NV's EBITDA Margin % for the quarter that ended in Dec. 2020 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2020 )/Revenue (Q: Dec. 2020 )
=-61.049/17.5
=-348.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV  (LTS:0RBP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Kiadis Pharma NV EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (LTS:0RBP) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (LTS:0RBP) Headlines

No Headlines